Cabozantinib Active Across Rarer, Heterogeneous, Non-Clear Cell RCCs (CME/CE)
(MedPage Today) -- A retrospective, real-world study
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news
More News: Study | Urology & Nephrology